PRIeRE tulip

Product Overview

PRIeRE tuLip is a South Korean cross-linked hyaluronic acid (HA) dermal filler developed and manufactured by ARUDA Co., Ltd. Specifically designed for lip-focused aesthetic applications, the formulation combines 26 mg/mL hyaluronic acid, 0.3% lidocaine, and vitamin B12 (cyanocobalamin). PRIeRE tuLip features a monophasic HA gel manufactured using ARUDA's proprietary HLD™ cross-linking technology, which combines high- and low-molecular-weight hyaluronic acid to achieve a cohesive gel structure. The product is supplied in a 1.1 mL pre-filled syringe, with one syringe per box.

PRIeRE tuLip is commercially positioned as a lip contouring and volumizing filler. Its formulation is designed to combine the structural characteristics of cross-linked hyaluronic acid with the distinctive reddish appearance associated with vitamin B12.

Unlike conventional transparent HA fillers, PRIeRE tuLip incorporates cyanocobalamin, a naturally red-colored form of vitamin B12. ARUDA describes this ingredient combination as part of its color-enhancing filler technology.

The formulation contains 26 mg/mL hyaluronic acid and 3 mg/mL lidocaine. Manufacturer specifications identify a monophasic gel structure, a degree of modification (MOD) of 1.25 mol%, and a storage modulus (G') of approximately 100 Pa.

PRIeRE tuLip belongs to ARUDA's broader PRIeRE hyaluronic acid product family. The range includes facial dermal fillers and a separate tuLip Booster formulation with different HA cross-linking characteristics.

In September 2026, PRIeRE tuLip received South Korean medical device authorization under permit number 26-709. The registered product is classified as a tissue-restoration biomaterial and is intended for temporary improvement of moderate to deep facial wrinkles in adults through physical soft-tissue restoration.

The manufacturer's lip-focused commercial positioning should be distinguished from the precise indications authorized in each regulatory market.

This TEOSQUARE product page provides professional buyers with information about PRIeRE tuLip's composition, hyaluronic acid technology, gel properties, packaging, intended aesthetic applications, storage considerations, and regulatory status.

Key Features

• 26 mg/mL Cross-Linked Hyaluronic Acid: Contains a high-concentration HA gel designed to provide temporary physical soft-tissue volume and structural support.
• Vitamin B12-Enhanced Formulation: Contains cyanocobalamin, a naturally red-colored form of vitamin B12 incorporated into the manufacturer's color-enhancing filler concept.
• 0.3% Lidocaine: Includes 3 mg/mL lidocaine, an amide-type local anesthetic intended to help reduce discomfort associated with professional filler administration.
• HLD™ Cross-Linking Technology: Uses ARUDA's proprietary manufacturing approach combining high- and low-molecular-weight HA to produce a cohesive, stabilized gel.
• Monophasic Gel Structure: Features a homogeneous gel formulation with manufacturer-reported rheological characteristics suitable for its commercial positioning.
• Storage Modulus of Approximately 100 Pa: Manufacturer technical specifications identify a G' value of approximately 100 Pa.
• Low Degree of Modification: Features a manufacturer-reported HA modification degree of 1.25 mol%.
• Lip Contouring Positioning: Commercially developed for enhancing the appearance of lip volume, definition, and natural-looking contours.
• 1.1 mL Pre-Filled Syringe: Supplied in a ready-filled syringe presentation, with one syringe per standard commercial box.
• South Korean Manufacturing: Developed and manufactured by ARUDA Co., Ltd., a South Korean medical aesthetics manufacturer.

Composition & Specifications

PRIeRE tuLip contains cross-linked sodium hyaluronate, lidocaine, and cyanocobalamin (vitamin B12).

Its principal structural component is cross-linked hyaluronic acid at 26 mg/mL. Lidocaine is included at 3 mg/mL, while cyanocobalamin contributes to the formulation's distinctive color-enhancing concept.

The precise concentration of cyanocobalamin has not been independently established from the available manufacturer-issued quantitative specifications.

Cross-Linked Hyaluronic Acid — 26 mg/mL

Hyaluronic acid is a naturally occurring glycosaminoglycan found in the extracellular matrix of connective tissues, including the skin.

It possesses strong hydrophilic properties, allowing it to interact with water and contribute to tissue hydration and viscoelasticity.

PRIeRE tuLip contains 26 mg/mL cross-linked hyaluronic acid, equivalent to a nominal 28.6 mg of HA in its 1.1 mL syringe.

Cross-linking introduces chemical connections between HA polymer chains, creating a stabilized gel structure with greater resistance to degradation than non-crosslinked HA.

This stabilized structure provides the physical basis for temporary soft-tissue filling and contour correction.

The high HA concentration is one of the manufacturer's principal distinguishing characteristics for PRIeRE tuLip.

However, HA concentration alone does not establish greater longevity, lifting capacity, or clinical superiority compared with other dermal fillers.

Vitamin B12 (Cyanocobalamin)

Cyanocobalamin is a chemically stable form of vitamin B12 with a characteristic red color.

Vitamin B12 is an essential water-soluble vitamin involved in normal cellular metabolism, DNA synthesis, and neurological function.

In PRIeRE tuLip, cyanocobalamin is incorporated into the manufacturer's color-enhancing HA formulation concept.

Its red coloration contributes to the distinctive appearance of the finished hyaluronic acid gel.

ARUDA commercially positions this combination for enhancing the appearance of natural lip color alongside the volume and contouring characteristics of cross-linked HA.

The manufacturer has also reported patent registration for a color-enhancing filler composition combining hyaluronic acid derivatives and vitamin B12.

However, the presence of red-colored vitamin B12 does not independently establish permanent lip pigmentation, a specific degree of color enhancement, or an identical cosmetic result in every patient.

Cyanocobalamin is a confirmed formulation ingredient, but its exact concentration has not been independently verified. Vitamin B12 should not be described as a permanent lip pigment or a clinically proven treatment for lip discoloration.

Lidocaine — 0.3%

Lidocaine is an amide-type local anesthetic commonly incorporated into injectable dermal fillers.

It temporarily reduces sensory nerve conduction by inhibiting voltage-gated sodium channels in nerve cell membranes.

This mechanism reduces the propagation of electrical signals associated with pain.

PRIeRE tuLip contains 3 mg/mL lidocaine, equivalent to 0.3%.

The manufacturer includes lidocaine to help reduce discomfort associated with professional filler administration.

Lidocaine does not eliminate procedural discomfort or prevent complications associated with injectable dermal fillers.

BDDE Cross-Linking Agent

BDDE, or 1,4-butanediol diglycidyl ether, is a cross-linking agent used in the manufacturing of certain stabilized hyaluronic acid fillers.

During manufacturing, BDDE creates chemical connections between HA polymer chains, contributing to the formation of a stabilized gel network.

ARUDA describes its manufacturing process as using controlled cross-linking and purification to reduce residual BDDE.

Residual BDDE is a manufacturing quality-control consideration, not an intended therapeutic ingredient.

The specific residual BDDE concentration should be verified from manufacturer-controlled quality documentation rather than inferred from the product's degree of modification.

The confirmed principal ingredients are cross-linked hyaluronic acid, lidocaine, and vitamin B12. The quantitative HA and lidocaine specifications are verified from manufacturer materials, while the exact vitamin B12 content and complete excipient declaration require additional product-specific documentation.

HLD™ Technology & Gel Characteristics

PRIeRE tuLip is manufactured using ARUDA's proprietary HLD™ cross-linking technology.

The technology combines high- and low-molecular-weight hyaluronic acid within a controlled cross-linking process.

According to the manufacturer's technical descriptions, this approach is intended to produce a dense but cohesive HA gel with material properties suitable for its commercial lip-contouring application.

High- and Low-Molecular-Weight HA

Hyaluronic acid polymers can differ in molecular weight, which influences their physical characteristics and behavior in solution.

ARUDA describes its HLD™ process as combining higher- and lower-molecular-weight HA during gel manufacturing.

The manufacturer reports that this approach supports a relatively dense and uniform cross-linked HA structure.

This manufacturing concept is intended to balance gel cohesion, structural support, and softness.

The exact molecular-weight distribution and relative proportions of the two HA fractions have not been independently established from the publicly available product specifications.

Monophasic Hyaluronic Acid Gel

PRIeRE tuLip is classified by ARUDA as a monophasic hyaluronic acid filler.

Monophasic HA gels are generally characterized by a relatively homogeneous gel structure rather than a suspension of distinct gel particles within a separate carrier phase.

Gel homogeneity and cohesivity are relevant to the physical behavior of injectable HA materials.

ARUDA positions the monophasic characteristics of PRIeRE tuLip as suitable for natural-looking contour correction.

However, a monophasic designation does not independently establish superior clinical integration, greater safety, or longer-lasting results.

Storage Modulus (G') — Approximately 100 Pa

Storage modulus, commonly represented as G', is a rheological measurement describing the elastic response of a material under oscillatory deformation.

In dermal fillers, G' is one of several material properties considered when evaluating a gel's mechanical characteristics.

ARUDA reports a G' value of approximately 100 Pa for PRIeRE tuLip.

This value provides a technical reference for the product's elastic behavior.

However, G' values depend on the measurement conditions, including temperature, oscillation frequency, and applied strain.

Therefore, direct comparisons between fillers require standardized testing conditions.

Degree of Modification (MOD) — 1.25 mol%

Degree of modification is a measure associated with the chemical modification of hyaluronic acid during cross-linking.

ARUDA identifies a MOD value of 1.25 mol% for PRIeRE tuLip.

This value characterizes the manufacturer's cross-linked HA formulation.

However, MOD is not identical to the concentration of residual free BDDE in the finished product.

A lower degree of modification does not independently guarantee a lower risk of adverse reactions or greater biocompatibility.

Resistance to Enzymatic Degradation

Hyaluronic acid can undergo degradation through enzymatic and non-enzymatic processes.

Cross-linking generally increases the resistance of HA gels to degradation compared with non-crosslinked HA.

ARUDA has published laboratory comparisons examining the degradation characteristics of its cross-linked HA formulations.

These tests provide material-level information about gel stability under specific experimental conditions.

Laboratory degradation resistance should not be interpreted as a direct prediction of the duration of clinical results in human tissue.

HLD™ Technology, monophasic structure, storage modulus, and MOD are manufacturing and material characteristics. Their presence does not establish clinical superiority without appropriate comparative evidence involving the finished product.

How PRIeRE tuLip Works

PRIeRE tuLip combines the physical filling characteristics of cross-linked hyaluronic acid with the red coloration of cyanocobalamin and the local anesthetic properties of lidocaine.

These ingredients have distinct roles within the finished formulation.

Physical Soft-Tissue Restoration

Cross-linked hyaluronic acid forms a hydrated gel capable of occupying space within soft tissue.

This physical characteristic provides the basis for temporary tissue restoration and contour correction.

PRIeRE tuLip contains a high-concentration HA gel designed to maintain cohesive material characteristics.

When used within an authorized indication, the gel can provide temporary correction of selected soft-tissue volume deficits and wrinkles.

Hyaluronic Acid and Hydration

Hyaluronic acid is highly hydrophilic and interacts with water molecules.

Within biological tissues, HA contributes to hydration and extracellular matrix properties.

The HA component of PRIeRE tuLip combines moisture-binding characteristics with the mechanical properties of a cross-linked gel.

The degree of hydration and physical correction depends on the finished formulation and individual tissue characteristics.

Vitamin B12 and Gel Color

Cyanocobalamin is a red-colored form of vitamin B12.

Its inclusion gives PRIeRE tuLip a distinctive reddish gel appearance.

ARUDA describes this as part of a technology intended to combine soft-tissue filling with a natural-looking lip color effect.

However, the visible coloration of the gel does not independently establish permanent lip pigmentation or a predictable change in the natural color of the treated tissue.

Temporary Local Anesthetic Action

Lidocaine temporarily inhibits sensory nerve signaling through voltage-gated sodium channel blockade.

This reduces the transmission of certain pain-related electrical impulses.

The lidocaine component is intended to support patient comfort during authorized professional administration.

Biodegradation of Hyaluronic Acid

Hyaluronic acid is biodegradable and gradually undergoes enzymatic and non-enzymatic breakdown.

Cross-linking modifies its degradation characteristics by creating a stabilized polymer network.

The resulting aesthetic effects are temporary rather than permanent.

The persistence of the material depends on its properties, tissue environment, and individual biological factors.

These mechanisms describe established HA and lidocaine properties together with the manufacturer's vitamin B12 formulation concept. They do not guarantee a particular degree of volumization, lip color enhancement, or duration of clinical results.

Professional Aesthetic Positioning

PRIeRE tuLip is commercially developed as a hyaluronic acid filler focused on the appearance of the lips.

ARUDA identifies lip volume, contour, and color enhancement among the principal objectives of the product's commercial design.

Lip Volume Enhancement

Cross-linked hyaluronic acid is widely used in aesthetic medicine for temporary soft-tissue volume restoration.

PRIeRE tuLip is commercially positioned for improving the appearance of lip fullness through the physical properties of its HA gel.

The manufacturer describes its 26 mg/mL HA concentration and cohesive gel characteristics as relevant to the product's volumizing concept.

Lip Contour Definition

Lip contours are influenced by individual anatomy, soft-tissue structure, and age-related changes.

PRIeRE tuLip is marketed for improving the appearance of lip definition and contour.

The manufacturer's formulation design emphasizes a balance between gel cohesion and softness.

Natural-Looking Lip Color

PRIeRE tuLip contains cyanocobalamin, which gives the formulation its characteristic reddish appearance.

ARUDA positions this feature as part of its color-enhancing lip filler concept.

However, clinical claims concerning increased lip redness, color uniformity, or persistent pigmentation require product-specific evidence.

Temporary Correction of Facial Wrinkles

The product's South Korean medical device registration identifies temporary improvement of moderate to deep facial wrinkles in adults through physical soft-tissue restoration.

This registered indication should be distinguished from the manufacturer's broader lip-focused commercial positioning.

Whether a particular lip augmentation or contouring procedure is included within the applicable authorized indication must be determined from the current product labeling and destination-country regulations.

Commercial descriptions of lip volumization, contour improvement, and color enhancement do not automatically establish approved indications. The current instructions for use and applicable national regulations determine permitted clinical applications.

PRIeRE tuLip vs. PRIeRE tuLip Booster

ARUDA markets two distinct lip-focused products within the PRIeRE range: PRIeRE tuLip and PRIeRE tuLip Booster.

Although both contain hyaluronic acid and vitamin B12, their HA formulations and product characteristics differ.

PRIeRE tuLip — Cross-Linked HA Filler

PRIeRE tuLip contains 26 mg/mL cross-linked hyaluronic acid, 0.3% lidocaine, and vitamin B12.

It is manufactured as a monophasic HA gel with physical properties intended to support temporary soft-tissue filling.

Its commercial positioning emphasizes lip contouring and volume enhancement.

PRIeRE tuLip Booster — Non-Crosslinked HA

PRIeRE tuLip Booster is a separate product containing 26 mg/mL non-crosslinked hyaluronic acid, mannitol, and vitamin B12.

The manufacturer positions Booster primarily for lip hydration and skin quality applications.

Because the HA is non-crosslinked, the formulation does not have the same chemically stabilized gel structure as PRIeRE tuLip.

This product page covers PRIeRE tuLip, the cross-linked HA filler. PRIeRE tuLip Booster is a separate formulation and should not be treated as a lidocaine-free version or interchangeable presentation of the same finished product.

Packaging & Product Presentation

PRIeRE tuLip is supplied as a sterile, pre-filled hyaluronic acid gel syringe.

The manufacturer's documented commercial presentation contains one 1.1 mL syringe per box.

1.1 mL Pre-Filled Syringe

Each PRIeRE tuLip syringe contains a nominal 1.1 mL of cross-linked HA gel.

The formulation has a reddish appearance associated with its vitamin B12 component.

The syringe is supplied as a pre-filled product rather than a dry preparation requiring reconstitution.

One-Syringe Commercial Package

The standard manufacturer-documented package contains one pre-filled syringe.

Distributor purchasing quantities may include multiple boxes, but these should not be confused with the original manufacturer packaging.

Buyers should verify the product name, original labeling, syringe volume, lot number, expiration date, and manufacturer information before procurement.

The 1.1 mL specification represents the nominal contents of the original syringe and is not a recommended administration quantity.

Storage & Handling

PRIeRE tuLip is a sterile cross-linked hyaluronic acid medical device supplied in a pre-filled syringe.

Commercial suppliers commonly describe storage between 2°C and 25°C with protection from direct sunlight.

However, the definitive storage conditions for the currently authorized finished product should be confirmed from the original manufacturer-issued labeling and instructions for use.

• Storage Temperature: Follow the validated temperature range stated on the original product label.
• Light Protection: Protect the product from direct sunlight and inappropriate environmental exposure.
• Freezing Protection: Avoid freezing unless explicitly permitted by the manufacturer's validated storage instructions.
• Original Packaging: Keep the syringe in its original manufacturer packaging until required for authorized professional use.
• Sterile Barrier Integrity: Do not use products with damaged packaging or evidence of compromised sterility.
• Single-Use Handling: Follow the manufacturer's instructions regarding single-patient use and disposal.
• Product Traceability: Confirm the complete product name, batch number, expiration date, and applicable regulatory labeling.

Shelf Life

Commercial export documentation has identified a shelf life of up to 36 months for PRIeRE tuLip.

However, the definitive expiration period for the supplied product should be established from its current manufacturer-issued labeling.

Original manufacturer documentation takes precedence over distributor specifications. The storage temperature and expiration date should be verified for the exact supplied product and manufacturing batch.

Safety & Regulatory Considerations

PRIeRE tuLip is an injectable hyaluronic acid medical device intended for use by appropriately qualified healthcare professionals.

Its use requires consideration of individual patient characteristics, product-specific contraindications, the intended anatomical region, and potential complications associated with injectable soft-tissue fillers.

Potential Adverse Reactions

Adverse reactions associated with injectable hyaluronic acid fillers may include localized pain, redness, swelling, bruising, tenderness, and itching.

Additional complications may include infection, hypersensitivity reactions, delayed inflammation, persistent nodules, granulomatous reactions, and product migration.

The frequency and severity of complications depend on the specific formulation, patient factors, and circumstances of administration.

Vascular Complications

Accidental introduction of dermal filler into a blood vessel can obstruct blood flow and result in serious tissue injury.

Potential complications include vascular occlusion, tissue ischemia, necrosis, visual impairment, blindness, and stroke.

These risks are not eliminated by high HA purity, low residual cross-linking agent levels, monophasic gel structure, or the presence of lidocaine.

Lidocaine-Related Precautions

PRIeRE tuLip contains 0.3% lidocaine.

Patients with known hypersensitivity to lidocaine, other amide-type local anesthetics, or relevant formulation ingredients may have contraindications to use.

Concomitant exposure to other local anesthetic products may require additional medical assessment.

Vitamin B12 and Formulation Considerations

PRIeRE tuLip contains cyanocobalamin, a form of vitamin B12.

The presence of vitamin B12 does not eliminate the possibility of hypersensitivity reactions or other complications.

Product-specific safety information should be reviewed for all formulation ingredients, including the color-enhancing component.

Hyaluronic Acid and Reversibility

Hyaluronic acid is biodegradable, and hyaluronidase may be used under appropriate medical circumstances to degrade HA fillers.

However, the potential use of hyaluronidase does not guarantee complete reversal of every complication or prevention of permanent tissue injury.

South Korean Medical Device Authorization

PRIeRE tuLip received South Korean medical device authorization on September 18, 2026.

The registered product is identified under permit number 26-709, with ARUDA Co., Ltd. as the authorization holder.

It is classified as a Class IV tissue-restoration biomaterial under the South Korean medical device regulatory system.

The registered intended use is temporary improvement of moderate to deep facial wrinkles in adults through physical tissue restoration using cross-linked sodium hyaluronate and cyanocobalamin.

The manufacturer's commercial promotion of lip augmentation and color enhancement should not be interpreted as confirmation that every such application is covered by the registered indication.

International Regulatory Considerations

Regulatory authorization is product-specific and country-specific.

South Korean medical device authorization does not automatically establish legal marketing authorization in the European Union, United States, or other international markets.

US FDA approval for PRIeRE tuLip has not been established.

The approval of other hyaluronic acid fillers does not automatically extend to PRIeRE tuLip.

Professional buyers should verify the current product registration, authorized indications, import eligibility, and distribution requirements applicable to their destination country.

This information is intended for professional product identification and commercial evaluation. It does not provide injection instructions, establish individual patient suitability, or authorize use outside applicable medical device regulations. Clinical use must follow the current manufacturer-issued instructions for use.

Frequently Asked Questions